Initial Statement of Beneficial Ownership (3)
September 24 2020 - 7:45PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Ogier Walter C |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/14/2020
|
3. Issuer Name and Ticker or Trading Symbol
Novus Therapeutics, Inc. [NVUS]
|
|
(Last)
(First)
(Middle)
C/O NOVUS THERAPEUTICS, INC., 19900 MACARTHUR BLVD., SUITE 550 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Street)
IRVINE, CA 92612
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | (1) | 8/31/2027 | Common Stock | 10415 | $0.6855 | D | |
| Stock Option (Right to Buy) | (1) | 8/31/2027 | Series X1 Convertible Preferred Stock (2) | 461.664 | $685.50 | D | |
| Stock Option (Right to Buy) | (1) | 1/28/2030 | Common Stock | 19190 | $0.495 | D | |
| Stock Option (Right to Buy) | (1) | 1/28/2030 | Series X1 Convertible Preferred Stock (2) | 850.662 | $495.00 | D | |
| Stock Option (Right to Buy) | (1) | 9/7/2030 | Common Stock | 68791 | $0.3808 | D | |
| Stock Option (Right to Buy) | (1) | 9/7/2030 | Series X1 Convertible Preferred Stock (2) | 3049.408 | $380.80 | D | |
| Explanation of Responses: |
| (1) | The option is fully vested. |
| (2) | Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. |
Remarks:
Ex. 24 - Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Ogier Walter C
C/O NOVUS THERAPEUTICS, INC.
19900 MACARTHUR BLVD., SUITE 550
IRVINE, CA 92612 | X |
|
|
|
Signatures
|
| /s/ Ryan A. Murr, as attorney-in-fact for Walter Ogier | | 9/24/2020 |
| **Signature of Reporting Person | Date |
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024
